AstraZeneca has sold the rights to develop tralokinumab drug to treat atopic dermatitis to LEO Pharma. LEO Pharma will pay AstraZeneca $115m in upfront payment, $1bn in milestones and up to mid-teen tiered percentage royalties on product sales. […]
Click here to view original web page at manufacturing.pharmaceutical-business-review.com
